Relevant bibliographies by topics / Claims vs. United States, 1941

Contents

  1. Journal articles
  2. Books
  3. Book chapters

Academic literature on the topic 'Claims vs. United States, 1941'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Claims vs. United States, 1941.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Claims vs. United States, 1941"

1

Vekeman, Francis, Marjolaine Gauthier-Loiselle, Elizabeth Faust, Patrick Lefebvre, Raquel Lahoz, Mei Sheng Duh, and Patricia Sacco. "Patient and Caregiver Burden Associated With Fragile X Syndrome in the United States." American Journal on Intellectual and Developmental Disabilities 120, no. 5 (September 1, 2015): 444–59. http://dx.doi.org/10.1352/1944-7558-120.5.444.

Full text
Abstract:
Abstract This study evaluated the incremental healthcare costs associated with Fragile X syndrome (FXS) for patients and their caregivers. Using administrative healthcare claims data (1999-2012), subjects with ≥ 1 FXS diagnosis (ICD-9-CM: 759.83) were matched 1:5 with non-FXS controls using high-dimensional propensity scores. Costs and resource utilization were examined. Among employees, payment for disability leave and absenteeism were also examined. We identified 590 FXS and 2,950 non-FXS individuals along with 647 and 2,611 caregivers, respectively. FXS patients and their caregivers experienced higher all-cause direct costs compared to control cohorts (total[SD]: $14,677[46,752] vs. $6,103[26,081]; $5,259[19,360] vs. $2,120[6,425], respectively, p < 0.05). Employed FXS patients and caregivers had higher indirect costs compared to their controls (total[SD]: $4,477[5,161] vs. $1,751[2,556]; $2,641[4,238] vs. $1,211[1,936], respectively, p < 0.05).
APA, Harvard, Vancouver, ISO, and other styles
2

Birnbaum, H., R. Kessler, V. Joish, D. Kelley, R. Ben-Hamadi, M. Hsieh, and P. Greenberg. "Healthcare Resource Utilization and Costs of Mild, Moderate, and Severe Depression in the Workforce in the United States." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70847-8.

Full text
Abstract:
Objective:Document the healthcare resource utilization and costs by severity for persons in the workforce with major depressive disorder (MDD).Methods:Using the National Comorbidity Survey-Replication data, workforce respondents (n=4,465) were categorized by clinical severity (not clinically depressed, mild, moderate, severe) using standard scales (CIDI/QIDS-SR). Outcomes measured over 12 months included prevalence of medical services/antidepressant use, average number of visits and days on antidepressants, prevalence of treatment adequacy, and medical/drug costs. Costs represent insurer payments to providers and were estimated by weighting utilization measures by unit costs obtained for similar services used by depressed patients in a U.S. employer claims database for the corresponding period (2000-2001). Outcomes were compared across depression severity groups using multivariate analyses adjusting for demographics.Results:Among the 539 depressed workforce respondents, 13.8% were mildly, 38.5% moderately and 47.7% severely depressed. A significant association existed between severity and prevalence of mental health services usage (19.1%, 27.2%, and 40.3% respectively, p< 0.01) and average number of mental health practitioner visits. The use of antidepressants increased with depression severity (21.1%, 27.3%, and 39.5% respectively, p< 0.01). Similarly, the adequacy of mental health services increased with depression severity (6.2%, 11.8%, and 21.3% respectively, p< 0.05). Average 12-month costs per MDD patient were substantially higher for severe vs. mild (mental health services: $697 vs. $388; general medical services: $138 vs. $53; anti-depressant usage $256 vs. $88).Conclusions:Among workforce respondents, there was a significant association between depression severity and treatment usage and costs, and between treatment adequacy and severity.
APA, Harvard, Vancouver, ISO, and other styles
3

Houtchens, Maria K., Natalie C. Edwards, Gary Schneider, Kevin Stern, and Amy L. Phillips. "Pregnancy rates and outcomes in women with and without MS in the United States." Neurology 91, no. 17 (September 28, 2018): e1559-e1569. http://dx.doi.org/10.1212/wnl.0000000000006384.

Full text
Abstract:
ObjectiveTo compare pregnancy prevalence and complications in women with and without multiple sclerosis (MS).MethodsThis retrospective US administrative claims study used data from January 1, 2006, to June 30, 2015. All data for women with MS were included. A nationally representative 5% random sample from approximately 58 million women without MS was used to compute the dataset. Annual pregnancy rates, identified via diagnosis/procedure codes and adjusted for covariates, were estimated via logistic regression. Claims for pregnancy and labor/delivery complications were compared using propensity score matching.ResultsFrom 2006 to 2014, the adjusted proportion of women with MS and pregnancy increased from 7.91% to 9.47%; the adjusted proportion without MS and with pregnancy decreased from 8.83% to 7.75%. The difference in linear trend (0.17% increase and 0.15% decrease in per-annum pregnancy rates) was significant (t statistic = 7.8; p < 0.0001). After matching (n = 2,115 per group), a higher proportion of women with MS than without had claims for premature labor (31.4% vs 27.4%; p = 0.005), infection (13.3% vs 10.9%; p = 0.016), cardiovascular disease (3.0% vs 1.9%; p = 0.028), anemia/acquired coagulation disorders (2.5% vs 1.3%; p = 0.007), neurologic complications (1.6% vs 0.6%; p = 0.005), sexually transmitted diseases (0.4% vs 0.1%; p = 0.045), acquired fetal damage (27.8% vs 23.5%; p = 0.002), and congenital fetal malformations (13.2% vs 10.3%; p = 0.004).ConclusionsPregnancy rates in this population of women with MS have been increasing. High rates of claims for several peripartum complications were observed in women with and those without MS. Claims data provide knowledge of interactions patients have with the health care system and are valuable initial exploratory analyses.
APA, Harvard, Vancouver, ISO, and other styles
4

Ranavaya, Mohammed I., and James B. Talmage. "Impairment and Disability Compensation Systems in the United States." Guides Newsletter 4, no. 6 (November 1, 1999): 1–13. http://dx.doi.org/10.1001/amaguidesnewsletters.1999.novdec01.

Full text
Abstract:
Abstract Although several states use the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides) when they evaluate individuals with impairments and disabilities, various disability systems exist in the United States. Disability and compensation systems have arisen to ensure that disadvantaged members of society with a medically determinable impairment, which may lead to a disability, have recourse to compensation from various sources, including state and federal workers’ compensation laws, veterans’ benefits, social welfare programs, and legal avenues. Each of these has differing definitions of disability, entitlement, benefits, procedures of claims application, adjudication, and the roles and relative weights assigned to medical vs administrative deliberations. Workers’ compensation statutes were enacted because of inadequacies of recovery from claims for injured workers under common law. Workers’ compensation is a no-fault system adopted to resolve the dilemmas of tort claims by providing automatic coverage to employees injured during the course of employment; in exchange for coverage, employees forego the right to sue the employer except for wanton neglect. Other workers’ compensation programs in the United States include the Federal Employees Compensation Act; the Federal Employers Liability Act (railroads); the Jones Act (Merchant Marine Act); the Longshore and Harbor Workers’ Compensation Act; the Department of Veterans Affairs; Social Security; and private, long-term disability insurance.
APA, Harvard, Vancouver, ISO, and other styles
5

Buckner, Tyler W., Iryna Bocharova, Kaitlin Hagan, Arielle G. Bensimon, Hongbo Yang, Eric Q. Wu, Eileen K. Sawyer, and Nanxin Li. "Health care resource utilization and cost burden of hemophilia B in the United States." Blood Advances 5, no. 7 (April 8, 2021): 1954–62. http://dx.doi.org/10.1182/bloodadvances.2020003424.

Full text
Abstract:
Abstract Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associated with differing clinical profiles of hemophilia B from a US health system perspective. Using the IBM MarketScan database (June 2011-February 2019), a claims-based algorithm was developed to identify 4 distinct profiles (mild, moderate, moderate-severe, and severe) in adult males with hemophilia B based on the frequency of hemorrhage events and factor IX replacement claims. Mean annual health care resource use (HRU) and costs were statistically compared between patients with hemophilia B (N = 454) and 1:1 demographic-matched controls (N = 454), both overall and with stratification by clinical profile. Compared with matched controls, patients with hemophilia B had a significantly higher comorbidity burden (Charlson Comorbidity Index, mean ± standard deviation [SD]: 0.9 ± 1.7 vs 0.3 ± 0.9, P &lt; .001). Across all clinical profiles, patients with hemophilia B had significantly higher HRU vs matched controls (mean ± SD: 0.3 ± 0.6 vs 0.1 ± 0.3 inpatient admissions; 0.6 ± 1.2 vs 0.2 ± 0.6 emergency department visits; 17.7 ± 22.9 vs 8.0 ± 11.0 outpatient visits; all P &lt; .001). Annual total health care costs per patient among patients with hemophilia B were more than 25-fold higher vs matched controls (mean ± SD: $201 635 ± $411 530 vs $7879 ± $29 040, respectively, P &lt; .001). Annual total health care costs per patient increased with increasing severity (mean ± SD: mild, $80 811 ± $284 313; moderate, $137 455 ± $222 021; moderate-severe, $251 619 ± $576 886; severe, $632 088 ± $501 270). The findings of this study highlight the substantial burden of illness associated with hemophilia B.
APA, Harvard, Vancouver, ISO, and other styles
6

Birnbaum, H., R. Ben-Hamadi, D. Kelley, M. Hsieh, B. Seal, P. Cremieux, and P. Greenberg. "Assessing the Relationship Between Compliance with Antidepressant Therapy and Costs Among Employees in the United States." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70731-x.

Full text
Abstract:
Objective:Assess effects of antidepressant compliance on healthcare and workplace costs.Methods:Using workplace survey data for 2 large employers’ healthcare claims (2004-2006), patient selection criteria considered depression diagnosis and antidepressant claims history. Employed respondents working in the past month were categorized by Medication Possession Ratio into compliance groups by quartiles; bottom/top quartiles were defined as compliant/non-compliant. Direct (medical/drug) costs were measured as insurer payments to providers; indirect (absenteeism/presenteeism) costs were based on one-month recall of workplace performance (hours worked/missed, self-rated performance), estimated as (hours missed x self-reported hourly income). Annualized, inflation-adjusted (2006) costs were compared between compliant/non-compliant groups using multivariate models controlling for baseline characteristics. Analyses were conducted for all patients and a subsample of diagnosed depression patients.Results:Among all patients (n=1,224), medical costs were numerically lower for compliant vs. non-compliant patients ($4,857 vs. $5,926, p=0.221); drug costs were significantly higher for compliant patients ($2,329 vs. $1,570, p=0.001). Indirect costs were not statistically different between compliant/non-compliant patients ($22,278 vs. $20,714, p=0.237). Among the depression subgroup (N=488), medical costs were numerically lower for compliant vs. non-compliant patients ($5,005 vs. $7,630, p=0.152) while drug costs were numerically higher for compliant patients ($2,550 vs. $1,829, p=0.153). Absenteeism costs were 30% lower for compliant patients ($7,725 vs. $11,040, p=0.038); presenteeism costs were not significantly different ($19,079 vs. $17,457, p=0.441).Conclusions:Absenteeism costs decrease significantly with compliance among depressed patients as do medical costs (not significantly). Further research is warranted regarding reason for poor antidepressant compliance and influence of compliance on costs.
APA, Harvard, Vancouver, ISO, and other styles
7

Sahay, Sandeep, Yuen Tsang, Megan Flynn, Peter Agron, and Robert Dufour. "Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study." Pulmonary Circulation 10, no. 4 (October 2020): 204589402096291. http://dx.doi.org/10.1177/2045894020962917.

Full text
Abstract:
Patients with portal hypertension may develop pulmonary hypertension. The economic implications of these comorbidities have not been systematically assessed. We compared healthcare resource utilization and costs in the United States between patients with co-existing portal hypertension and pulmonary hypertension (pulmonary hypertension cohort) and a matched cohort of portal hypertension patients without pulmonary hypertension (control cohort). In this retrospective analysis, adult pulmonary hypertension and control patients were identified from the Optum® Clinformatics® Data Mart database between 1 July 2014 and 30 June 2018. All patients had ≥2 claims with diagnosis codes for portal hypertension; pulmonary hypertension patients had ≥2 claims with diagnosis codes for pulmonary hypertension; controls could not have pulmonary hypertension diagnoses or any claims for pulmonary arterial hypertension-specific medications. Controls were matched to pulmonary hypertension patients by age, sex, Charlson comorbidity index score, and liver diseases. We assessed 12-month healthcare resource utilization and costs. Each cohort included 146 patients. During follow-up, pulmonary hypertension cohort patients were more likely than controls to experience a hospitalization (51% vs. 32%, P = 0.0014) and an emergency room visit (55% vs. 41%, P = 0.026). The average annual total cost was higher in pulmonary hypertension patients than for matched controls ($119,912 vs. $81,839, P < 0.0001). After covariate adjustment, costs for pulmonary hypertension cohort patients were 1.47 times higher than those for controls ( P = 0.0197). These findings suggest that patients with portal hypertension and co-existing pulmonary hypertension are at a greater risk for hospitalization and incur higher mean annual total costs than portal hypertension patients without pulmonary hypertension.
APA, Harvard, Vancouver, ISO, and other styles
8

Khorana, Alok A., Mehul Dalal, Jay Lin, and Gregory Clayton Connolly. "Health care costs associated with venous thromboembolism in select high-risk ambulatory solid tumor patients in the United States." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6059. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6059.

Full text
Abstract:
6059 Background: Venous thromboembolism (VTE) is an increasingly common complication of cancer and its treatment, including chemotherapy. VTE has significant clinical consequences, including mortality. However, contemporary data on the healthcare costs of cancer-associated VTE are limited. We examined the real-world economic burden of VTE in ambulatory patients initiating chemotherapy for select common high-risk solid tumors. Methods: Healthcare claims data (2004-2009) from the IMS/PharMetrics Patient-Centric database were collected for propensity score-matched adult cancer (lung, colorectal, pancreas, stomach, bladder and ovary) patients with VTE (n=912) and without VTE (n=2,736) after initiating chemotherapy. Healthcare resource utilization (inpatient, outpatient medical, and outpatient prescription drug claims) and costs were compared between the two cohorts during 12 months’ follow-up after the index VTE event. Incremental costs of VTE were adjusted for demographic and clinical covariates. Results: Cancer patients with VTE had ~3-times as many all-cause hospitalizations (mean 1.38 vs. 0.55 per patient) and days in hospital (10.2 vs. 3.4 per patient), and more outpatient claims (331 vs. 206 per patient) than matched cancer patients without VTE (all P<0.0001). Cancer patients with VTE incurred significantly higher overall (all-cause) inpatient costs (mean $21,299 vs. $7,459 per patient), outpatient costs (mean $53,660 vs. $34,232 per patient) and total healthcare costs (mean $74,959 vs. $41,691 per patient) than cancer patients without VTE (all P<0.0001). Total VTE-related healthcare costs were (mean) $9,247 per VTE patient over 12 months. Adjusted incremental all-cause healthcare costs of VTE were (mean) $30,538 per patient across the selected tumors, ranging from $11,946 per patient for gastric cancer to $38,983 per patient for pancreatic cancer. Conclusions: VTE results in significant inpatient and outpatient resource utilization, and increased all-cause (in addition to VTE-related) healthcare costs. Measures to prevent outpatient cancer-associated VTE may reduce healthcare utilization and costs in high-risk cancer patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Farrar, Mallory, Robert Farber, Ginny P. Sen, Charles Yonan, and Jean Lin Chan. "Real-World Evidence of Clinical Outcomes in Patients With Assumed Classic Congenital Adrenal Hyperplasia in the United States." Journal of the Endocrine Society 5, Supplement_1 (May 1, 2021): A93—A94. http://dx.doi.org/10.1210/jendso/bvab048.187.

Full text
Abstract:
Abstract Background: Classic congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder, usually due to a deficiency in the 21-hydroxylase enzyme, that results in impaired cortisol synthesis and excess androgen production. Patients with classic CAH experience both disease-related features from excess androgens and treatment-related complications from the chronic, supraphysiologic use of glucocorticoids (GCs) often required for androgen control. This study was conducted to evaluate the demographics and clinical characteristics of adult and pediatric patients in the United States (US) with assumed classic CAH based on International Classification of Diseases (ICD) codes, GC prescriptions, and medical claims. Methods: Analyses were based on longitudinal patient-level data from the Decision Resources Group Real World Evidence repository, which links medical claims, prescription claims, and electronic health records from &gt;300 million US patients. Data were analyzed for patients aged ≥18 years (adult) and &lt;18 years (pediatric) with assumed classic CAH based on ICD 9/10 codes associated with “adrenogenital disorders” and whose proportion of days covered with a GC in 2018–2019 was &gt;75%. These patients were matched 1:3 with a control cohort based on age, gender, geographic region, and insurance type. Both assumed CAH and control cohorts had continuous coverage with at least 1 medical claim and 1 pharmacy claim in each year, 2018–2019. Results: Of 1,111 patients with assumed classic CAH, 778 were ≥18 years old (65% female; mean age [±SD], 43±17 years) and 333 were &lt;18 years old (51% female; mean age [±SD], 11±4.7 years). Both adult and pediatric patients with assumed classic CAH were more likely than matched controls (adult N=2334; pediatric N=999) to experience events that could be related to chronic GC use, including infection (adult: 49.9% vs 37.3% [control]; pediatric: 49.5% vs 40.0%), weight gain (adult: 5.9% vs 2.5%; pediatric: 9.0% vs 2.6%), and moon face (adult: 44.0% vs 0.1%; pediatric: 37.8% vs 0.1%); all P&lt;0.01 vs control. Adult patients were more likely than matched controls to experience acne (6.0% vs 3.6%), hirsutism (8.1% [47/508] vs 5.5% [84/1524]), and infertility (1.7% vs 0.4%); all P&lt;0.01. Pediatric patients were more likely to experience pubertal development issues (10.5% vs 1.8%), acne (8.4% vs 5.1%), and advanced bone age (1.2% vs 0.1%); all P&lt;0.05. Conclusions: Compared to matched controls, both adult and pediatric patients with assumed classic CAH had significantly more disease-related comorbidities and potential GC treatment-related conditions, indicating the challenges with current GC treatments. This study was limited by the assumed nature of classic CAH due to lack of a specific ICD code, but the combination of chronic GC use (&gt;75% days) with the diagnosis code most likely used in these patients (adrenogenital disorder) supports the validity of this analysis.
APA, Harvard, Vancouver, ISO, and other styles
10

Patterson, Brandon J., Chi-Chang Chen, Catherine B. McGuiness, Lisa I. Glasser, Kainan Sun, and Philip O. Buck. "17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States." Open Forum Infectious Diseases 7, Supplement_1 (October 1, 2020): S31. http://dx.doi.org/10.1093/ofid/ofaa439.062.

Full text
Abstract:
Abstract Background Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥ 50 years of age (YOA). The vaccine is administered in a two-dose sequence with a 2- to 6-month interval; however, the Center for Disease Control & Prevention has advised against restarting a series after the prescribed window. This study describes an assessment of 2nd dose completion and compliance of RZV in the US. Methods Primary analysis was conducted on a cohort ≥ 50 YOA who received an initial RZV dose between October 2017 and September 2018 as indicated in the IQVIA longitudinal prescription claims or medical claims databases. Subjects were required to have ≥ 1 year of observable time post initial dose. A sensitivity analysis was conducted using all eligible subjects regardless of observable time post initial dose. Endpoints of analyses were monthly and cumulative 2nd dose label-compliant proportions at 6 months and completers by 12-month intervals and time to completion from initial RZV vaccine administration with stratifications by age, sex, claim source and payer type. Results The primary sample included 1,225,088 subjects, while the sensitivity analysis included 7,097,441 (Table 1). Overall, 2nd RZV dose completion was 70.4% within 6 months and 81.8% within 12 months. Minimal variation for 12-month completion was demonstrated across age (77.2–84.5%), sex (81.7–81.9%), and Commercial vs. Medicare (80.9–83.0%). However, larger variations were seen across claim sources and other payer type, with medical claims (64.9%), Medicaid patients (72.8%) and Cash patients (74.7%) having lower rates at 12 months (Table 2). Overall, the average time to completion was around 4 months regardless of stratification except by claims source, with medical claims taking 5 months on average to complete. The sensitivity analysis of the variable follow-up cohort demonstrated findings consistent with that of the primary sample. Conclusion Assessment of RZV suggests high levels of completion across age, sex, payer type and claim sources. More effort is needed to understand barriers to completion rates in Medicaid patients and settings where vaccination claims are processed outside of the vaccine recipient’s pharmacy benefit. Disclosures Brandon J. Patterson, PharmD, PhD, GSK (Employee, Shareholder) Chi-Chang Chen, PhD, MSPharm, GSK (Research Grant or Support) Catherine B. McGuiness, MA, MS, GSK (Research Grant or Support)Pfizer (Shareholder) Lisa I. Glasser, MD, GSK (Employee, Shareholder) Kainan Sun, MS, PhD, GSK (Research Grant or Support) Philip O. Buck, PhD, MPH, ORCID: 0000-0002-3898-3669, GSK (Employee, Shareholder)
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Claims vs. United States, 1941"

1

Mapp, Wayne. The Iran-United States Claims Tribunal: The first ten years, 1981-1991 : an assessment of the tribunal's jurisprudence and its contribution to international arbitration. Manchester: Manchester University Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

The Iran-United States Claims Tribunal: The first ten years, 1981-1991 : an assessment of the tribunal's jurisprudence and its contribution to international arbitration. Manchester: Manchester University Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Commission, United States Guam War Claims Review. Report on the implementation of the Guam Meritorious Claims Act of 1945. Washington, DC]: Guam War Claims Review Commission, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United States. Congress. House. Committee on Interior and Insular Affairs. Subcommittee on Insular and International Affairs. To amend the Organic Act of Guam: Hearing before the Subcommittee on Insular and International Affairs of the Committee on Interior and Insular Affairs, House of Representatives, One Hundred First Congress, first session, on H.R. 2024 ... hearing held in Washington, DC, July 27, 1989. Washington: U.S. G.P.O., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

United States. Congress. House. Committee on Interior and Insular Affairs. Subcommittee on Insular and International Affairs. To amend the Organic Act of Guam: Hearing before the Subcommittee on Insular and International Affairs of the Committee on Interior and Insular Affairs, House of Representatives, One Hundred First Congress, first session, on H.R. 2024 ... hearing held in Washington, DC, July 27, 1989. Washington: U.S. G.P.O., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Millman, Chad. The detonators: The secret plot to destroy America and an epic hunt for justice. New York, NY: Little, Brown, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Millman, Chad. The detonators: The secret plot to destroy America and an epic hunt for justice. New York: Little, Brown, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Carmen, Quintanilla, and University of Guam. Richard Flores Taitano Micronesian Area Research Center., eds. Inventory of papers from the Guam War Claims Review Commission, U.S. Public law 107-333. [Mangilao, Guam]: Manuscripts Collection, Richard F. Taitano Micronesian Area Research Center, University of Guam, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

United States. Congress. House. Committee on Foreign Affairs. Subcommittee on International Economic Policy and Trade., ed. Issues affecting the question of United States relations with Vietnam: Hearing before the Subcommittees on Asian and Pacific Affairs and on International Economic Policy and Trade of the Committee on Foreign Affairs, House of Representatives, One Hundred First Congress, first session, November 17, 1989. Washington: U.S. G.P.O., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States-Iranian relations: Hearing before the Subcommittee on Europe and the Middle East of the Committee on Foreign Affairs, House of Representatives, One Hundred First Congress, first session, November 9, 1989. Washington: U.S. G.P.O., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Claims vs. United States, 1941"

1

Bazyler, Michael J., Kathryn Lee Boyd, Kristen L. Nelson, and Rajika L. Shah. "United States." In Searching for Justice After the Holocaust, 463–78. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780190923068.003.0046.

Full text
Abstract:
The United States entered World War II on the side of the Allied forces in 1941. While no immovable property located in the United States was confiscated during the war, the United States was involved with armistice agreements and the 1947 Paris Peace Treaties, which included clauses requiring the protection, return, and/or compensation of property. The United States was also involved in bilateral claims settlement agreements with several European countries, to address compensation for confiscated or nationalized property during and after the war. In the 1990s, the United States was a facilitator in large-scale Holocaust restitution. Several lawsuits against sovereigns and private parties involving stolen Jewish property were filed in American courts and continue today. The political branches of the U.S. government were involved in the settlement of Holocaust restitution lawsuits. The United States endorsed the Terezin Declaration in 2009 and the Guidelines and Best Practices in 2010.
APA, Harvard, Vancouver, ISO, and other styles
2

Woodward, Jude. "Can China rise peacefully?" In The US vs China. Manchester University Press, 2017. http://dx.doi.org/10.7228/manchester/9781526121998.003.0003.

Full text
Abstract:
The case that China must be contained rests on the premise that it is – or is about to – engage in a coercive expansion of its influence in ‘Central Asia, the South China Sea, the internet and outer space’ and it is only a matter of time before China tries ‘to push the United States out of the Asia-Pacific region, much the way the United States pushed the European great powers out of the Western hemisphere in the 19th century’. China’s rise is cast as dangerous for the security of its neighbours and world peace, with the only guarantee of regional and global stability the maintenance of the leading role of the US, particularly in Asia itself. This chapter examines the truth of these claims in the light of the China’s own explanation of the direction of its foreign policy. It argues that while China’s foreign policy has become more emphatic in pursuing its international interests, especially relating to trade and energy security, that there is a great deal of difference between greater confidence in pursuing China’s national interests and a new aggressive stance.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Claims vs. United States, 1941' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography